EA202191256A1 - Способы лечения рака на моделях, имеющих мутации esr1 - Google Patents

Способы лечения рака на моделях, имеющих мутации esr1

Info

Publication number
EA202191256A1
EA202191256A1 EA202191256A EA202191256A EA202191256A1 EA 202191256 A1 EA202191256 A1 EA 202191256A1 EA 202191256 A EA202191256 A EA 202191256A EA 202191256 A EA202191256 A EA 202191256A EA 202191256 A1 EA202191256 A1 EA 202191256A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
estrogen receptor
receptor alpha
methods
models
Prior art date
Application number
EA202191256A
Other languages
English (en)
Inventor
Хитиша Пател
Тиру БИХАНИ
Хайке Арлт
Нианджун Тао
Original Assignee
Радиус Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Радиус Фармасьютикалс, Инк. filed Critical Радиус Фармасьютикалс, Инк.
Publication of EA202191256A1 publication Critical patent/EA202191256A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем документе раскрываются способы лечения устойчивого к лекарственному средству положительного по рецептору эстрогена альфа рака у субъекта, имеющего мутантный рецептор эстрогена альфа, при этом способ предусматривает введение субъекту терапевтически эффективного количества элацестранта или его фармацевтически приемлемых соли или сольвата, при этом мутантный рецептор эстрогена альфа содержит одну или несколько мутаций, выбранных из группы, состоящей из D538G, Y537X1, L536X2, P535H, V534E, S463P, V392I, E380Q и их комбинаций, при этом X1 представляет собой S, N или C; и X2 представляет собой R или Q. Согласно некоторым вариантам осуществления устойчивый к лекарственному средству положительный по рецептору эстрогена альфа рак выбран из группы, состоящей из рака молочной железы, рака матки, рака яичника и рака гипофиза.
EA202191256A 2018-12-06 2019-12-06 Способы лечения рака на моделях, имеющих мутации esr1 EA202191256A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Publications (1)

Publication Number Publication Date
EA202191256A1 true EA202191256A1 (ru) 2021-10-06

Family

ID=69158304

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191256A EA202191256A1 (ru) 2018-12-06 2019-12-06 Способы лечения рака на моделях, имеющих мутации esr1

Country Status (13)

Country Link
US (1) US20220016052A1 (ru)
EP (1) EP3890835A1 (ru)
KR (1) KR20210100135A (ru)
AU (1) AU2019392908A1 (ru)
BR (1) BR112021010141A2 (ru)
CA (1) CA3121918A1 (ru)
EA (1) EA202191256A1 (ru)
IL (1) IL283655A (ru)
JO (1) JOP20210138A1 (ru)
MA (1) MA54393A (ru)
MX (1) MX2021006412A (ru)
SG (1) SG11202105915UA (ru)
WO (1) WO2020118202A1 (ru)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7019422B2 (ja) * 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法

Also Published As

Publication number Publication date
WO2020118202A1 (en) 2020-06-11
CA3121918A1 (en) 2020-06-11
US20220016052A1 (en) 2022-01-20
SG11202105915UA (en) 2021-07-29
BR112021010141A2 (pt) 2021-08-24
MX2021006412A (es) 2021-07-21
MA54393A (fr) 2021-10-13
EP3890835A1 (en) 2021-10-13
JP2022511497A (ja) 2022-01-31
KR20210100135A (ko) 2021-08-13
IL283655A (en) 2021-07-29
AU2019392908A1 (en) 2021-06-10
JOP20210138A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
RU2017140674A (ru) Способы лечения рака
HRP20210200T1 (hr) Kombinirana antitumorska imunoterapija
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MY186977A (en) Tetrasubstituted alkene compounds and their use
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
JP2018502120A5 (ru)
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
UA124238U (uk) Спосіб лікування раку молочної залози
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
PH12019500025A1 (en) Cancer treatment combinations
EA202191283A1 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
MX2021002321A (es) Nuevos metodos.
EA202092036A1 (ru) Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
MX2020009668A (es) Métodos novedosos.
EA202092540A1 (ru) Комбинации для лечения рака
MX2020013335A (es) Metodos novedosos.
JP2019532047A5 (ru)
MX2019006131A (es) Metodos para tratar cancer de mama positivo para prlr.
MX2021002322A (es) Nuevos metodos.
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
MX2020002741A (es) Uso de gaboxadol en el tratamiento de narcolepsia.
EA202191256A1 (ru) Способы лечения рака на моделях, имеющих мутации esr1
EA202193178A1 (ru) Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина